0
Sign In  | Subscribe
21 May 2002, Vol 136, No. 10>
Summaries for Patients | 21 May 2002

Alendronate Improves Osteoporosis in Elderly Women Living in Long-Term Care Facilities FREE

[+] Article and Author Information

The summary below is from the full report titled “Alendronate Improves Bone Mineral Density in Elderly Women with Osteoporosis Residing in Long-Term Care Facilities. A Randomized, Double-Blind, Placebo- Controlled Trial.” It is in the 21 May 2002 issue of Annals of Internal Medicine (volume 136, pages 742-746). The authors are SL Greenspan, DL Schneider, MR McClung, PD Miller, TJ Schnitzer, R Bonin, ME Smith, P DeLucca, GJ Gormley, and ME Melton.


Ann Intern Med. 2002;136(10):I54-. doi:10.7326/0003-4819-136-10-200205210-00004
Text Size: A A A

What is the problem and what is known about it so far?

As women get older, their bones become more fragile (a condition called osteoporosis). As a result, the risk of fracture increases. Up to 86% of female nursing home residents have osteoporosis. Alendronate is a medication used to treat osteoporosis. Many studies have shown that treatment of osteoporosis with alendronate in younger women improves bone density and prevents fractures. No one knows if elderly women with osteoporosis can be treated effectively.

Why did the researchers do this particular study?

To find out if elderly women living in long-term care facilities could be treated effectively with alendronate and whether they could tolerate the side effects of this medicine.

Who was studied?

327 women living in 25 different nursing homes and assisted living centers across the United States who had documented osteoporosis. None of the women were bed-bound. The average age of participants was 78.5 years.

How was the study done?

Using a computerized coin flip, the researchers assigned the women to receive daily doses of either alendronate or a placebo for 24 months. All participants in both groups also received vitamin D, which helps the body retain and use calcium consumed in the diet. Calcium supplements were also given to women whose diets did not already contain enough calcium. The researchers measured bone strength (bone mineral density, or BMD) at the lower portion of the spine and at the hip bone. In addition, they did blood tests to evaluate whether the body was making new bone or losing bone. The researchers also kept track of side effects of alendronate.

What did the researchers find?

The elderly women taking alendronate had greatly improved BMD compared with women taking placebo. Blood tests also showed favorable effects on bone in the alendronate group. The occurrence of side effects did not significantly differ between the two groups.

What were the limitations of the study?

The study did not have enough participants to evaluate whether alendronate significantly decreased the number of fractures in the elderly women, and it could not determine how long medication should be given.

What are the implications of the study?

In elderly women, osteoporosis may be treated effectively by using alendronate.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general jounals
BMJ 2010;341:c5893-c1494.

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Want to Subscribe?

Learn more about subscription options

Register Now for a free account
Advertisement

Related Content

Customize your page view by dragging & repositioning the boxes below.

In the Clinic
The Polycystic Ovary Syndrome
Ann Intern Med. 2011;154(3):ITC2-1.
Breast Cancer Screening and Prevention
Ann Intern Med. 2010;152(7):ITC4-1.
Menopause
Ann Intern Med. 2009;150(7):ITC4-1.
Topic Collections
PubMed Articles
Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
Journal of medical economics Issue date: 2012
Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
Journal of managed care pharmacy : JMCP Issue date: 2012 May

Annals of Internal Medicine

Other Resources

Copyright © 2013 The American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Want to Subscribe?

Learn more about subscription options

Register Now for a free account
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)